| Titre : | Understanding the Role of Pharmaceutical-Led Public–Private Partnerships in Advancing SDG 3.4 in Low- and Middle-Income Countries: A Qualitative Study on Stakeholder’s Perspectives |
| Auteurs : | Clara Fillol ; Ecole des hautes études en santé publique (EHESP) (Rennes, FRA) |
| Type de document : | Mémoire |
| Année de publication : | 2025 |
| Description : | 39p. |
| Langues: | Anglais |
| Classement : | MPH/ (Mémoires MPH à partir de 2024) |
| Mots-clés : | Partenariat public privé (PPP) ; Maladie non transmissible ; Industrie pharmaceutique ; Système santé ; Objectifs du développement durable (ODD) ; Gouvernance |
| Résumé : |
Background: Noncommunicable diseases (NCDs) are a leading cause of premature mortality in low- and middle-income countries (LMICs), where health systems often face resource and capacity constraints. Pharmaceutical-led public–private partnerships (PPPs) have emerged as a mechanism to expand access to medicines, strengthen health systems, and support national NCD strategies. However, evidence on their effectiveness, sustainability, and governance in LMIC contexts remains limited.
Methods: This qualitative study draws on 17 semi-structured interviews with experts from sectors relevant to PPPs, including the pharmaceutical industry, NGOs, multilateral organizations, academia, government, and health consulting. Participants were selected for their experience in NCD prevention and control in LMICs across sub-Saharan Africa, South Asia, and Latin America. Thematic analysis was utilized to identify recurring themes. Results: Participants identified improved access to medicines, health system strengthening, and capacity building as key benefits of pharmaceutical-led PPPs. Enabling conditions included strong government leadership, multisectoral collaboration, community engagement, and strong monitoring frameworks. Barriers included misalignment of objectives between public and private partners, governance and accountability gaps, sustainability risks due to short-term funding, and limited measurable impact on mortality. Frequent shifts in national health priorities were also cited as a challenge to long-term engagement. Conclusion: Pharmaceutical-led PPPs can contribute significantly to advancing SDG 3.4 in LMICs, but their impact is contingent on strong governance, alignment with national priorities and sustainable financing models. Integrating PPPs into national health strategies and investing in prevention and local capacity are critical to transforming short-term projects into sustainable, system-strengthening initiatives. |
| Diplôme : | Master MPH of public health |
| Plan de classement simplifié : | Master of Public Health - master international de Santé Publique (MPH) |
| En ligne : | https://documentation.ehesp.fr/memoires/2025/mph/clara_fillol.pdf |
Documents numériques (1)
Full text URL |
